Trial Profile
A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 Pneumonia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Mar 2023
Price :
$35
*
At a glance
- Drugs Lenzilumab (Primary) ; Dexamethasone; Remdesivir
- Indications COVID-19 pneumonia; Cytokine release syndrome
- Focus Registrational; Therapeutic Use
- Acronyms LIVE-AIR
- Sponsors Humanigen
- 06 Jul 2022 Results published in the Thorax
- 06 Jul 2022 Results presented in a Humanigen Media Release.
- 06 Jul 2022 According to a Humanigen media release, data from a sub-analysis of this trial published in Thorax.